FGEN - FibroGen, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Francisco,
United States
Type: Equity
FGEN price evolution
FGEN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $56.18 | $140.71 | $105.73 | $113.69 |
| Short term investments | $71.86 | $121.9 | ||
| Net receivables | $83.33 | $6.41 | $37.08 | $12.55 |
| Inventory | $23.94 | $25.4 | $27.34 | $41.56 |
| Total current assets | $244.53 | $209.46 | $278.17 | $331.56 |
| Long term investments | $8.57 | $7.43 | $6.95 | |
| Property, plant & equipment | $9.7 | $72.13 | $76.92 | $81.22 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $83.74 | $87.7 | $91.97 | |
| Total investments | $8.57 | $79.3 | $128.85 | |
| Total assets | $264.42 | $293.2 | $365.87 | $423.53 |
| Current liabilities | ||||
| Accounts payable | $9.24 | $9.94 | $4.35 | $17.96 |
| Deferred revenue | $140.74 | $159.98 | $170.29 | |
| Short long term debt | $15.53 | $15.23 | $14.08 | |
| Total current liabilities | $190.53 | $148.59 | $196.73 | $217.67 |
| Long term debt | $90.98 | $185.39 | $186.94 | $189.88 |
| Total noncurrent liabilities | $334.99 | $355.29 | $368.06 | |
| Total debt | $200.92 | $202.17 | $203.96 | |
| Total liabilities | $508.09 | $483.58 | $552.02 | $585.73 |
| Shareholders' equity | ||||
| Retained earnings | -$1907.48 | -$1890.4 | -$1874.85 | -$1841.92 |
| Other shareholder equity | -$5.63 | -$3.81 | -$6.51 | -$6.88 |
| Total shareholder equity | -$232.34 | -$228.12 | -$204.17 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $113.69 | $135.82 | $171.22 | $678.39 |
| Short term investments | $121.9 | $266.31 | $233.97 | $8.14 |
| Net receivables | $12.55 | $16.3 | $17.4 | $41.88 |
| Inventory | $41.56 | $40.44 | $31.02 | $16.53 |
| Total current assets | $331.56 | $492.83 | $474.06 | $755.11 |
| Long term investments | $6.95 | $11.48 | $173.69 | $5.04 |
| Property, plant & equipment | $81.22 | $100.93 | $120.15 | $63.25 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $91.97 | $117.26 | $299.76 | $71.73 |
| Total investments | $128.85 | $277.79 | $407.66 | $13.19 |
| Total assets | $423.53 | $610.09 | $773.82 | $826.84 |
| Current liabilities | ||||
| Accounts payable | $17.96 | $30.76 | $26.1 | $24.79 |
| Deferred revenue | $170.29 | $198.46 | $202.66 | $145.02 |
| Short long term debt | $14.08 | $10.29 | $10.96 | $12.33 |
| Total current liabilities | $217.67 | $273.56 | $225.5 | $163.19 |
| Long term debt | $189.88 | $17.05 | $88.78 | $25.39 |
| Total noncurrent liabilities | $368.06 | $338 | $319.21 | $222.2 |
| Total debt | $203.96 | $139.22 | $99.73 | $37.72 |
| Total liabilities | $585.73 | $631.53 | $544.71 | $385.39 |
| Shareholders' equity | ||||
| Retained earnings | -$1841.92 | -$1557.69 | -$1264.03 | -$974.01 |
| Other shareholder equity | -$6.88 | -$5.72 | -$4.16 | -$4.5 |
| Total shareholder equity | -$204.17 | -$21.45 | $209.15 | $422.18 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $50.64 | $55.9 | $27.14 | |
| Cost of revenue | $5.18 | $25.75 | $5.41 | |
| Gross Profit | $45.46 | $30.15 | $21.73 | |
| Operating activities | ||||
| Research & development | $34.11 | $38.39 | $51.7 | |
| Selling, general & administrative | $22.28 | $22.82 | $24.22 | |
| Total operating expenses | $56.38 | $61.21 | $75.93 | |
| Operating income | -$10.92 | -$31.06 | -$54.2 | |
| Income from continuing operations | ||||
| EBIT | -$11.02 | -$27.9 | -$51.08 | |
| Income tax expense | -$0.26 | $0.03 | $0.08 | |
| Interest expense | $4.78 | $5 | $5.07 | |
| Net income | ||||
| Net income | -$15.54 | -$32.93 | -$56.23 | |
| Income (for common shares) | -$15.54 | -$32.93 | -$56.23 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $147.75 | $140.73 | $235.31 | $176.32 |
| Cost of revenue | $18.85 | $20.28 | $12.87 | $8.87 |
| Gross Profit | $128.9 | $120.45 | $222.44 | $167.45 |
| Operating activities | ||||
| Research & development | $282.86 | $296.79 | $387.04 | $252.92 |
| Selling, general & administrative | $115.25 | $124.69 | $123.92 | $106.41 |
| Total operating expenses | $410.72 | $421.48 | $510.97 | $359.33 |
| Operating income | -$281.81 | -$301.02 | -$288.53 | -$191.88 |
| Income from continuing operations | ||||
| EBIT | -$268.7 | -$291.86 | -$288.6 | -$186.53 |
| Income tax expense | $0 | $0.36 | $0.35 | $0.36 |
| Interest expense | $15.53 | $1.44 | $1.07 | $2.4 |
| Net income | ||||
| Net income | -$284.23 | -$293.65 | -$290.02 | -$189.29 |
| Income (for common shares) | -$284.23 | -$293.65 | -$290.02 | -$189.29 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$15.54 | -$32.93 | -$56.23 | |
| Operating activities | ||||
| Depreciation | $0.78 | $0.82 | $1.88 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $8.59 | $8.76 | $9.3 | |
| Total cash flows from operations | -$39.87 | -$59.29 | -$18.32 | |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.03 | -$0.25 | |
| Investments | $72.25 | $51.3 | $10.49 | |
| Total cash flows from investing | $124.27 | $72.24 | $51.28 | $10.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.12 | $0.04 | ||
| Net borrowings | -$0.01 | -$0.01 | -$0.05 | |
| Total cash flows from financing | -$0.26 | $0.03 | -$0.17 | -$0.25 |
| Effect of exchange rate | $0.84 | $2.58 | $0.22 | $1.1 |
| Change in cash and equivalents | $17.31 | $34.98 | -$7.95 | -$7.23 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$284.23 | -$293.65 | -$290.02 | -$189.29 |
| Operating activities | ||||
| Depreciation | $9.93 | $10.6 | $14.81 | $22.05 |
| Business acquisitions & disposals | $0.66 | -$35 | -$25 | -$2.83 |
| Stock-based compensation | $50.77 | $65.6 | $71.16 | $72.72 |
| Total cash flows from operations | -$315.02 | -$145.93 | -$82.23 | $81.6 |
| Investing activities | ||||
| Capital expenditures | -$2.52 | -$3.73 | -$5.19 | -$3.99 |
| Investments | $155.52 | $127.85 | -$396.79 | $459.31 |
| Total cash flows from investing | $153.66 | $89.12 | -$426.97 | $452.49 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $52.14 | $4.18 | $12.7 | $37.83 |
| Net borrowings | $70.85 | $47.76 | -$5.89 | -$13.02 |
| Total cash flows from financing | $122.75 | $46.78 | -$0.56 | $13.34 |
| Effect of exchange rate | -$3.4 | -$5.48 | $2.6 | $4.7 |
| Change in cash and equivalents | -$42.01 | -$15.52 | -$507.17 | $552.13 |
News
Fundamentals
| Market cap | $1.08B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 100.77M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.56 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -2.87 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.28 |
| Quick ratio | 1.16 |